ENMD-2076
作者：齊岳
發布時間：2023-08-23
09:36:16
點擊數：
產品名稱：ENMD-2076
產品描述：
| 產品描述 | ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα. |
| 靶點活性 | FLT3:1.86 nM, Aurora A:14 nM, RET:10.4 nM, Src:20.2 nM, VEGFR3/FLT4:15.9 nM |
| 體外活性 | 在MDA-MB-231異種移植模型中, ENMD-2076可以抑制形成新血管,同時使形成的血管發生退化.在HT29異種移植模型中,ENMD-2076對Flt3以及VEGFR2 / KDR和FGFR1 / 2的激活持續發揮抑制作用.在H929人漿細胞瘤異種移植物中,口服ENMD-2076（50-200 mg / kg /day）,其中磷酸 - 組蛋白3（pH3）,Ki-67顯著降低,裂解的胱天蛋白酶-3顯著增加. |
| 體內活性 | ENMD-2076作用于PI3K/AKT通路,下調凋亡抑制蛋白。ENMD-2076能夠抑制aurora A和B激酶,且誘導細胞周期停在G2/M 期。在多種作用于血管生成的激酶中（IC50=1.86-120 nM）,ENMD-2076能夠發揮作用,比如VEGFR2/KDR 和VEGFR3, FGFR1和FGFR2, 及PDGFRα。在多種人類實體瘤和血*細胞系中（IC50=0.025 -0.7 μM）,ENMD-2076使細胞停滯在G2/M 期,誘導細胞凋亡 |
| 激酶實驗 | Kinase assays: Recombinant Aurora A and B kinase enzymes and appropriate PanVera Z'-Lyte kinase assay kits are purchased. Assays are carried out in kinase assay buffer (50 mM of HEPES, pH 7.5, 10 mM of MgCl2, 5 mM of EGTA, 0.05% Brij-35) supplemented with 2 mM of DTT. Activities are determined at an ATP concentration equivalent to the apparent Km for each enzyme, and an enzyme concentration that results in approximately 30% phosphorylation of the peptide substrate after 1 hour. Dose–response curves of relative enzyme activity versus ENMD-2076 concentration are plotted with Grafit and used to calculate IC50 values. Potency of ENMD-2076 free base against a select panel of 100 kinase enzymes is determined using the SelectScreen kinase profiling service. ATP concentrations are at the apparent Km for each enzyme or 100 μM if the apparent Km could not be reached. Percent inhibition is determined at an ENMD-2076 free base concentration of 1 μM; for kinases where significant inhibition is noted, IC50 values are determined by generating full 10-point dose–response curves. |
| 細胞實驗 | The antiproliferative effect of ENMD-2076 on adherent tumor cell lines is measured by plating 500 cells per well in a 96-well plate and incubating with ENMD-2076 for 96 hours. Cellular proliferation is measured using the sulforhodamine B assay. The leukemia-derived, nonadherent cell lines are assayed by plating 5 × 103 cells per well in a 96-well plate. The cells are incubated with ENMD-2076 for 48 hours and then survival is assayed using the Alamar Blue reagent. To measure the effect of ENMD-2076 on VEGF- and fibroblast growth factor (FGF)-induced proliferation of human umbilical vein endothelial cell (HUVEC), cells are serum starved for 6 hours, then treated with ENMD-2076 free base, and stimulated with 5 ng/mL bFGF or 25 ng/mL VEGF (R and D Systems) for 72 hours. Cell proliferation is measured using WST-(Only for Reference) |
| 分子量 | 375.48 |
| 分子式 | C21H25N7 |
| CAS No. | 934353-76-1 |
存儲
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
溶解度
DMSO: 97 mg/mL (258.3 mM)
H2O: 1 mg/mL (2.66 mM)
Ethanol: <1 mg/mL
( < 1 mg/mL refers to the product slightly soluble or insoluble )
聯系我們：
郵箱：2519696869@qq.com
QQ: 2519696869
電話：18066853083
微信：18066853083
公司介紹：
西安齊岳生物科技有限公司是集化學科研和定制與一體的高科技化學公司。業務范圍包括化學試劑和產品的研發、生產、銷售等。涉及產品為通用試劑的分銷、非通用試劑的定制與研發，涵蓋生物科技、化學品、中間體和化工材料等領域。
主營產品：COF、MOF單體系列：三蝶烯衍生物、金剛烷衍生物、四苯甲烷衍生物、peg、上轉換、石墨烯、光電材料、點擊化學、凝集素、載玻片、蛋白質交聯劑、脂質體、蛋白、多肽、氨基酸、糖化學等。
